Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas

Bläker, Michael; Schmitz, Michael; Gocht, Andreas; Burghardt, Sylvia; Schulz, M; Bröring, D. C.; Pace, Andrea; Greten, H.; Weerth, Andreas de

doi:10.1016/j.jhep.2004.03.018

Cited by 59 publications

(58 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously, expression of estrogen receptors and somatostatin receptors was reported in HCCs (45,52), suggesting potential role of estrogen and somatostatin in HCC. Therefore, hormonal therapy such as tamoxifen, megestrol, octreotide and lanreotide was extensively studied for the treatment of advanced HCC.…”

Section: Hormonal Therapymentioning

confidence: 94%

Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy

Kim

Talati

Kim

2017

J. Gastrointest. Oncol.

244

168

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with poor prognosis.The incidence of HCC and HCC-related deaths have increased over the last several decades. However, the treatment options for advanced HCC are very limited. Sorafenib remains the only drug approved for systemic treatment for advanced HCC. However, prior to sorafenib era conventional cytotoxic chemotherapies have been studied in advanced HCC. In this review, clinical studies of systemic chemotherapy for advanced HCC will be summarized and discussed.

show abstract

Section: Hormonal Therapymentioning

confidence: 94%

Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy

Kim

Talati

Kim

2017

J. Gastrointest. Oncol.

244

168

View full text Add to dashboard Cite

show abstract

“…(14) In rats, sstr have been shown to be expressed in activated hepatic stellate cells in CCl 4 -treated rats (15) and low levels of sstr2 mRNA were present in normal liver and hepatoma.…”

mentioning

confidence: 99%

Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide

et al. 2007

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death, and its incidence is increasing worldwide. Due to the known risk factors (mainly hepatitis B and C viruses), we believe there is a rationale for a chemopreventive approach to treat HCC. Here, based on described in vitro data, we evaluated the preventive effects of lanreotide, a somatostatin analog, on the induction of early carcinogenic events. We monitored preneoplastic foci induced by a two-stage initiation/promotion model of hepatocarcinogenesis in male Wistar rats, using diethylnitrosamine and 2-acetylaminofluorene. Lanreotide was given starting the day after the first diethylnitrosamine injection. By quantitative morphometry, we showed that lanreotide significantly decreases the size of induced preneoplastic foci. Analysis of proliferation and apoptosis assessed by immunohistochemistry, showed decreased proliferation and increased cell death in rats treated with lanreotide. As these events were associated with a significant decreased expression of the cell cycle regulator cyclin D1 and an increased expression of the cyclin-dependent kinase inhibitor p27 kip1 compared to the non-treated group, it is tempting to speculate that these factors are involved in the favorable effect of lanreotide. In conclusion, lanreotide significantly decreases early carcinogenic transformation in a two-step rat model. As lanreotide has a low toxicity profile, we believe it would be interesting to evaluate its effect in chemoprevention of HCC. (Cancer Sci 2007; 98: 1831-1839) H CC represents a major public health problem. Its incidence is in constant progression, with 2-5 new cases per 100 000 inhabitants/year in western countries and more than 20 per 100 000 inhabitants/year in Asia.(1,2) Curative treatment can only be proposed in 10-20% of cases.The main risk factors of HCC development are cirrhosis and hepatitis B and C that induce genetic alterations leading to preneoplastic, then neoplastic changes. The persistence of infection and/or cirrhosis often leads to tumoral relapse after surgical resection, observed in approximately 20% per year. Therefore, chemoprevention could play an important role in the therapeutic strategy of this disease.In experimental carcinogenesis, preneoplastic foci of altered hepatocytes emerge weeks or months before the appearance of hepatocellular adenomas and HCC.(3) Similar progression has been described in human hepatocarcinogenesis.(4) This fact has led to the development of a number of in vivo systems to study early neoplasia in rat liver.(5) The initiation-promotion or two-stage model of cancer development mimics the early events of the latent period of human carcinogenesis. The initiation stage of cancer development can be produced in rat liver by injection of DEN, (6) a carcinogen that causes DNA ethylation and mutagenesis.(7) Furthermore, DEN has been shown to induce tumors in rodents that closely mimic a subclass of human HCC. Somatostatin analogs (octreotide and lanreotide) are molecules that are widely...

show abstract

“…As in our experience, the somatostatin receptor (SSTR) expression in HCC is independent of tumour stage, differentiation, underlying liver disease and/or histological type (Blaker et al, 2004) and none of these parameters is therefore predictive of somatostatin analogue treatment response. As said, selection of HCC patients with more sensitive methods of SSTR expression (reverse transcription -polymerase chain reaction or immunohistochemistry, among which a high correlation is present), have not and will not change the picture.…”

Section: Sirmentioning

confidence: 84%

“…One could therefore say that the chances for the drug to work in receptor-negative patients are quite small. In previous papers, the percentage of receptor-positive patients was not defined (Treiber et al, 2006) or showed wide variability (Reynaert et al, 2004), even in relation to the type of receptor tested (Blaker et al, 2004).…”

Section: Sirmentioning

confidence: 96%